Evidence map›Paper›PMID 40996826›Full record

ArticleEuropean heart journal2025

Cardiovascular magnetic resonance phenotyping: the new standard for primary prevention implantable cardioverter-defibrillator decision-making in cardiac sarcoidosis.

Harold Mathijssen, Parag H Bawaskar, Chetan Shenoy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Harold MathijssenDepartment of Cardiology, St Antonius Hospital, Nieuwegein, The Netherlands.
Parag H BawaskarCardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA.
Chetan ShenoyCardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA.ORCID 0000-0001-8877-4999

Funding

Immunologic basis of cardiac disease after severe COVID-19R01HL158756 · NHLBI · UNIVERSITY OF MINNESOTA · PI BAKER, JASON V, SHENOY, CHETAN · 2022 to 2025
$2.7M
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related CardiotoxicityK23HL132011 · NHLBI · UNIVERSITY OF MINNESOTA · PI SHENOY, CHETAN N · 2016 to 2020
$884k
A Myocardial Approach to Identify the Cause of CardiomyopathyR21HL172296 · NHLBI · UNIVERSITY OF MINNESOTA · PI SHENOY, CHETAN · 2024 to 2025
$233k
Cardiac Magnetic Resonance Imaging Guided Risk Stratification in Cardiac SarcoidosisR03HL157011 · NHLBI · UNIVERSITY OF MINNESOTA · PI SHENOY, CHETAN N · 2021 to 2022
$155k
NHLBI NIH HHS K23 HL132011NHLBI NIH HHS R01 HL158756NHLBI NIH HHS R03 HL157011NHLBI NIH HHS R21 HL172296NIH HHS K23HL132011NIH HHS R01HL158756NIH HHS R03HL157011NIH HHS R21HL172296
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40996826
PMCPMC12682365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.